Endocrine Abstracts

Background: High-grade neuroendocrine tumours (HGNETs) of the oesophagus are extremely rare and few cases have been reported worldwide. Here we aim to understand clinical profile, treatment strategy and outcomes for oesophageal HGNETs.Methods: We report a single-centre retrospective review of 21 patients with oesophageal HGNETs treated between 2011–2016. Data on incidence, tumour location, stage at presentation, histopathology, treatment protocol an...

Background: Pulmonary carcinoids (PC) are rare neuroendocrine tumors (NETs). The course of PCs is considered to be indolent, but patients with advanced disease have low survival rates and their treatment options are limited. As PCs are under-represented in trials, therapeutic decisions are based on evidence extrapolated from other types of NETS. Capecitabine-Temozolamide (CAPTEM) has demonstrated significant efficacy in pancreatic NETs. However, its role in PCs is still unexpl...

Introduction: Platinum-etoposide is considered standard-of-care first-line treatment for patients diagnosed with advanced EP-PD-NECs. The optimal platinum-etoposide schedule remains undefined; carboplatin is often substituted for cisplatin, although quality data is lacking.Methods: Electronic records of patients with advanced EP-PD-NEC treated with carboplatin-etoposide (06/09-02/17) were reviewed retrospectively, with aim to provide real-life efficacy/s...